Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. - Wikidata - awgldk - TriplyDB

Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.

Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.

http://www.wikidata.org/entity/Q45275265

about

Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib Sorafenib for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis: a systematic review of comparative studies Challenges of advanced hepatocellular carcinoma Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival.Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib.Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis.Current management of hepatocellular carcinoma: an Eastern perspective.Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study.On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study.Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors.Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma.Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib.Down-regulation of UBC9 increases the sensitivity of hepatocellular carcinoma to doxorubicin.Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan.High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models.Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis.Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma.Editorial: sorafenib toxicity, a biomarker of effect?Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients.Sorafenib for Recurrent Hepatocellular Carcinoma after Liver Transplantation

P2860

Q26765210-CDEE034B-CAEA-4CF5-849C-01549B04094F Q26777892-92EFC946-E9D5-4FF9-A972-7E1204EBE174 Q28076867-C4056008-A370-4AC2-B2BB-34C802405B63 Q30240748-ED131C1A-892A-486E-BB06-E038C7F0EBDD Q33829431-64F79992-B545-4999-A4DA-A3640AADCDDA Q36750713-71E7F0CB-183F-4866-91AE-4E5A85920252 Q37737863-B2D971CD-2FA3-4F8C-B7E8-CD8CCF60D89E Q38410816-EE210554-3994-41E0-8814-DF6D640B67DD Q38830457-78C46997-BED5-469B-A9E4-0013E1AA9F77 Q38933901-A2E877B1-BCCE-44BD-8892-9EE676F0ACF0 Q39019421-1357B6EB-4CB8-4F7B-AE68-A11AE552F8B3 Q39030388-44385E1C-933E-4B09-9B89-98A39709AF69 Q39473582-1DDE2933-5259-43B6-BCC0-0B88C9802BDA Q41472744-940896DA-8AF8-4A47-8F7E-54DFF2A75378 Q43470197-2925F809-FF1D-46F2-B141-E9DB483FDE1A Q47608670-4B101E3A-FF6B-4080-AA70-BA27D5133282 Q48166586-D02BF705-DEFA-4ED6-8957-6B632BB6C2ED Q50512896-76D24E82-1E05-42C6-AF8A-4B9B7646A1C8 Q54521075-CD913C34-8D9E-4C10-B54B-1BC2A248CE0B Q55476332-9BA19F32-63CD-43C5-AF15-046A44A29F75 Q58556654-C6ABD661-1310-4444-B1B1-337EAFF5EA38

P2860

Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.

http://www.wikidata.org/entity/Q45275265

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Clinical parameters predictive ...... nced hepatocellular carcinoma.

@en

Clinical parameters predictive ...... nced hepatocellular carcinoma.

@nl

type

label

Clinical parameters predictive ...... nced hepatocellular carcinoma.

@en

Clinical parameters predictive ...... nced hepatocellular carcinoma.

@nl

prefLabel

Clinical parameters predictive ...... nced hepatocellular carcinoma.

@en

Clinical parameters predictive ...... nced hepatocellular carcinoma.

@nl

P1433

Q45275265-1D8CC811-9C5F-4DC9-AC22-FEA19648C0C0

P1476

Q45275265-527B9967-AB61-4D15-AB56-443F397CD27A

P2093

Q45275265-02E6D45E-E30D-4617-88BB-BFD0ED831CA1

Q45275265-0F3DE845-73A6-4ED9-8AA4-C440B3CC68BC

Q45275265-1D79034D-62EA-4D7A-9E0A-2655235F2C08

Q45275265-2985D3D7-E1E4-48C3-B469-527C419E0D72

Q45275265-30BF143B-E723-4F55-AA22-18B3DE424466

Q45275265-518DDBD6-294C-4291-BEC9-9999E34AE1DC

Q45275265-52E8F00D-584D-4C8D-8D0E-B042898F0AA9

Q45275265-8627C4EC-E546-4649-9CA0-8384CBE7A552

Q45275265-895F7747-3985-488D-BDB6-F545E0FC11D8

Q45275265-BB50ADE8-C73C-417D-8FD7-525740EC4877

P2860

Q45275265-00D22362-863C-4E76-932A-0E236DFD40FA

Q45275265-0E58BE39-1A07-4BAA-87A3-982CDAD8B678

Q45275265-23282283-6615-4E3E-A538-04D3150831BE

Q45275265-24F2DBBD-1B5F-4D2A-8B02-EB70E268A4BF

Q45275265-2CAF704C-EB70-41CC-BEC6-4BDC1CD54E52

Q45275265-31C02974-D635-4EC0-8FBD-49671EBC122B

Q45275265-3995B208-8FE8-43F9-A801-A30BD123EC92

Q45275265-56B4626B-5A63-489B-A53D-1EA9966F5CC6

Q45275265-5C48A6A3-F9D2-448B-9B0E-6B0BB14C6745

Q45275265-75C1A4F6-F3E1-45FE-9F3F-5F1BF3CC83BE

P304

Q45275265-C23A2E26-B448-4E11-83B7-EEA2A983BDCD

P31

Q45275265-AF883EC8-4B6A-416E-97EA-364C72916566

P356

Q45275265-50FF1D5A-9406-4594-9479-FB1D98E78AAD

P433

Q45275265-379E93AB-4DF2-464F-8660-E71E70B7A61B

P478

Q45275265-B4E799BB-C434-4CC3-82E8-C20F814ECD0B

P577

Q45275265-9DC217B7-CD68-4C20-8E82-A86F8E655506

P698

Q45275265-5DB4452D-E893-4F67-A22D-BB717B3ABC36

P356

P1433

Liver International

P1476

Clinical parameters predictive ...... nced hepatocellular carcinoma.

@en

P2093

Byung Chul Yoo

http://www.w3.org/2001/XMLSchema#string

Geum-Youn Gwak

http://www.w3.org/2001/XMLSchema#string

Ho Yeong Lim

http://www.w3.org/2001/XMLSchema#string

Hyo Keun Lim

http://www.w3.org/2001/XMLSchema#string

Joon Hyeok Lee

http://www.w3.org/2001/XMLSchema#string

Ju-Yeon Cho

http://www.w3.org/2001/XMLSchema#string

Kwang Cheol Koh

http://www.w3.org/2001/XMLSchema#string

Moon Seok Choi

http://www.w3.org/2001/XMLSchema#string

Seung Woon Paik

http://www.w3.org/2001/XMLSchema#string

Yang Won Min

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Management of hepatocellular carcinoma: An update

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

Sorafenib in advanced hepatocellular carcinoma

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits.

Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study

Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib

Economic evaluation of sorafenib in unresectable hepatocellular carcinoma.

Sorafenib-associated hand-foot syndrome in Japanese patients.

P304

950-957

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/LIV.12168

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23601249

http://www.w3.org/2001/XMLSchema#string